Gold prices edge higher on raised Fed rate cut hopes
Patricia Carr, Senior Vice President and Chief Accounting Officer at Jazz Pharmaceuticals (NASDAQ:JAZZ), recently sold shares of the company, according to a regulatory filing. On March 10, Carr sold 1,140 ordinary shares at an average price of $137.81 per share, totaling approximately $157,103. The company maintains impressive financial health with a 92.36% gross profit margin and trades at an attractive P/E ratio of 15.2x.
Earlier, on March 7, Carr disposed of 1,333 shares at $138.23 each, valued at approximately $184,260. This transaction was carried out to satisfy tax obligations from the vesting of previously granted restricted stock units. Following these transactions, Carr holds 7,012 shares directly. InvestingPro analysis suggests Jazz Pharmaceuticals is currently undervalued, with management actively buying back shares. Discover 10+ additional exclusive insights and detailed financial analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Jazz Pharmaceuticals has been the subject of several analyst updates and company developments. H.C. Wainwright raised its price target for Jazz Pharmaceuticals to $217, maintaining a Buy rating, following the company’s acquisition of Chimerix (NASDAQ:CMRX), which includes the promising drug dordaviprone. UBS also upgraded Jazz Pharmaceuticals to a Buy, increasing the price target to $179, citing confidence in the company’s base business and potential from its Ziihera pipeline. Truist Securities lifted its target to $230, reflecting optimism about dordaviprone’s potential impact on Jazz’s financials, while RBC Capital adjusted its target slightly down to $178, maintaining an Outperform rating but noting uncertainties in the company’s pipeline and leadership.
Moreover, Needham increased its price target to $210, buoyed by Jazz Pharmaceuticals’ recent earnings release and positive updates, including a settlement on Epidiolex that extends market exclusivity. Jazz Pharmaceuticals’ financial guidance for 2025 aligns with consensus estimates, projecting revenue at approximately $4.275 billion. The company also reported R&D savings, which may indicate efficient resource allocation. These developments collectively highlight Jazz Pharmaceuticals’ strategic moves and ongoing efforts to strengthen its financial and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.